News and reporting on prostate cancer.
The study is part of an effort to drive health plan coverage for Exosome's ExoDx Prostate IntelliScore prostate cancer test.
The device allows researchers to track cancer growth for a longer period of time, enabling improved observations and analysis, according to the researchers.
Ambry will provide genetic testing in NorthShore’s Genomic Health Initiative in hopes of moving precision medicine into clinical practice.
The companies will market Angle's Parsortix system for harvesting circulating tumor cells with Qiagen's liquid biopsy product portfolio.
The company said the dramatic increase was driven by a one-time buy-out of patents related to colorectal cancer by Exact Sciences.
The genomic test is designed to help doctors decide which patients are at low enough risk that they can be more conservatively managed.
In Genome Biology this week: computational tool to uncover cancer driver mutations, microbial species linked to ankylosing spondylitis, and more.
Researchers identified shifts in regulatory features and enhanced NOTCH signaling pathway activation in prostate tumors containing a TMPRSS2-ERG2 gene fusion.
The company has made agreements with two cancer diagnostics firms — GenomeDx, and Cynvenio — bundling its hereditary germline analysis with their somatic tests.
Total revenue for the quarter was $85.5 million compared to $82 million in Q2 2016, while net loss shrank to $2.7 million or $.08 per share.
In PLOS this week: Mycobacterium abscessus linked to gastric conditions, placental gene expression changes associated with preterm birth, and more.
The Guardian reports that UK universities are looking into ways to reduce labs' reliance on single-use plastics.
People with certain gene variants tend to not like vegetables, particularly bitter ones, CNN reports.
MIT's Technology Review reports on a company's genetic test that gauges an embryo's susceptibility to certain diseases.